Sagimet Biosciences Inc. SGMT R3KPHARMA
Company Overview
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +11.80% |
| 6 Months: | +99.07% |
| 3 Months: | +64.01% |
| 1 Month: | +18.21% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)63.33 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SGMT Sagimet Biosciences Inc. R3KPHARMA | 10.71 | -8.50 | $659.64M | 0.00% | -51.08% | -24.37% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 2.00M | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 19.86M | 11.93M | 14.33M | 10.77M | 11.71M |
| Operating Income | - | -7.24M | -7.69M | -6.76M | -7.06M | -7.45M | -8.77M | -10.59M | -16.90M | -19.86M | -11.93M | -14.33M | -10.77M | -11.71M |
| EBITDA | - | - | - | - | - | - | - | - | - | -19.86M | -11.93M | -14.33M | -10.77M | -11.71M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | -18.18M | -10.39M | -12.91M | -9.57M | -10.65M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -8.73M | -7.10M | -7.47M | -6.59M | -6.79M | -6.35M | -6.63M | -8.12M | -14.62M | -18.18M | -10.39M | -12.91M | -9.57M | -10.65M |
| Diluted EPS | - | -38.37 | -40.34 | -35.58 | -35.80 | -0.35 | -0.23 | -0.25 | -0.45 | -0.56 | -0.32 | -0.40 | -0.29 | -0.33 |
| R&D Expense | - | 6.37M | 6.84M | 4.49M | 4.68M | 4.96M | 5.26M | 6.31M | 12.65M | 15.34M | 7.25M | 9.73M | - | 7.00M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 2.00M | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 31.05M | 32.74M | 54.45M | 56.89M |
| Operating Income | - | -31.05M | -30.74M | -54.45M | -56.89M |
| EBITDA | - | -31.05M | -30.74M | -54.45M | -56.89M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | - | -30.50M | -27.88M | -45.57M | -51.04M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -30.50M | -27.88M | -45.57M | -51.04M |
| Diluted EPS | - | -1.38 | -2.66 | -1.45 | -1.58 |
| R&D Expense | - | 24.92M | 19.78M | 38.44M | 39.05M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 33.03M | 96.72M | 160.26M | 116.48M |
| Current Assets | - | 32.79M | 96.65M | 152.77M | 116.40M |
| Cash & Equivalents | - | 158.00K | 75.14M | 75.84M | 35.02M |
| Inventory | - | - | - | - | - |
| Receivables | - | - | - | - | - |
| Total Liabilities | - | 219.98M | 5.65M | 4.45M | 5.10M |
| Current Liabilities | - | 5.28M | 5.65M | 4.45M | 5.10M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 211.00K | 65.00K | 78.00K | 78.00K |
| Total Equity | - | -186.95M | 91.06M | 155.81M | 111.38M |
| Shares Outstanding | - | 22.17M | 22.90M | 32.20M | 32.52M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -24.49M | -23.77M | -42.44M | -45.65M |
| Investing Cash Flow | - | -32.01M | 12.58M | -61.68M | 4.56M |
| Financing Cash Flow | - | -73.00K | 86.17M | 104.82M | 275.00K |
| Capital Expenditure | - | - | - | - | - |
| Free Cash Flow | - | -24.49M | -23.77M | -42.44M | -45.65M |
| Net Change in Cash | - | -56.57M | 74.98M | 701.00K | -40.82M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | -1,537.0% | - | - |
| Net Margin % | - | - | -1,393.8% | - | - |
| ROE % | - | 16.3% | -30.6% | -29.2% | -45.8% |
| ROCE % | - | -111.9% | -33.8% | -35.0% | -51.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 10.68% | 6.58M | $72.93M |
| 2 | Balyasny Asset Management LP | 5.89% | 3.63M | $40.21M |
| 3 | Woodline Partners LP | 4.87% | 3.00M | $33.28M |
| 4 | SilverArc Capital Management, LLC | 4.75% | 2.93M | $32.47M |
| 5 | Vanguard Capital Management LLC | 4.17% | 2.57M | $28.46M |
| 6 | Affinity Asset Advisors, Llc | 4.06% | 2.50M | $27.70M |
| 7 | BVF Inc. | 4.06% | 2.50M | $27.73M |
| 8 | Caligan Partners, LP | 4.06% | 2.50M | $27.73M |
| 9 | Federated Hermes, Inc. | 3.39% | 2.09M | $23.14M |
| 10 | Great Point Partners LLC | 3.30% | 2.03M | $22.51M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SGMT
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announc…
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
All clinical trial sites identified and CRO retained Patient screening expected to begin in October 2026, with first patient to be enrolled shortly after FOSTER CITY, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasda…
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announce…
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data
Sagimet Biosciences (NASDAQ:SGMT) plans to begin a Phase III study of its oral fatty acid synthase, or FASN, inhibitor denifanstat in moderate-to-severe acne within the next several months, following positive results from a China-based Phas…
Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
Phase 3 clinical trial of denifanstat in moderate to severe acne patients in the U.S. on track to initiate in second half of 2026FOSTER CITY, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stag…
Sagimet Making 'Good Progress' in Bringing Denifanstat to US Patients, Wedbush Securities Says
Sagimet Biosciences (SGMT) is making "good progress" in advancing denifanstat as a treatment for mod
SGMT — Frequently Asked Questions
What is the current share price of Sagimet Biosciences Inc. (SGMT)?
As of 2026-09-19 21:16 PDT, Sagimet Biosciences Inc. (SGMT) trades at $10.71 on NasdaqGM. Its 52-week range is $4.55 to $10.99.
What is the market capitalisation of SGMT?
Sagimet Biosciences Inc. (SGMT) has a market capitalisation of $659.64M on NasdaqGM.
What is the P/E ratio of SGMT?
SGMT trades at a trailing price-to-earnings (P/E) ratio of -8.50. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.67.
What is the return on equity (ROE) of SGMT?
SGMT has a return on equity (ROE) of -24.37%. Its return on capital employed (ROCE) is -51.08%.
Is SGMT a good stock to buy?
This page provides a data-driven analysis of Sagimet Biosciences Inc. (SGMT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.